Results 271 to 280 of about 1,671,061 (305)
Some of the next articles are maybe not open access.

Cardiotoxicity of Immune Checkpoint Inhibitors

Current Treatment Options in Cardiovascular Medicine, 2019
Immunotherapies, particularly immune checkpoint inhibitors (ICI), are revolutionary cancer therapies being increasingly applied to a broader range of cancers. Our understanding of the mechanism, epidemiology, diagnosis, and treatment of cardiotoxicity related to immunotherapies remains limited.
Lili, Zhang   +8 more
openaire   +2 more sources

Melanoma and Immune Checkpoint Inhibitors

Current Oncology Reports, 2018
Prognosis of patients with advanced melanoma is dismal with a median overall survival of about 8 months and 5-year overall survival from a diagnosis of metastatic disease of roughly 10%. However, immune checkpoint inhibitors have brought indispensable benefits to melanoma patients.
Masutaka, Furue   +5 more
openaire   +2 more sources

The future of immune checkpoint therapy

Science, 2015
Immune checkpoint therapy, which targets regulatory pathways in T cells to enhance antitumor immune responses, has led to important clinical advances and provided a new weapon against cancer. This therapy has elicited durable clinical responses and, in a fraction of patients, long-term remissions where patients exhibit no clinical signs of cancer for ...
Padmanee, Sharma, James P, Allison
openaire   +2 more sources

Immune checkpoint inhibitor myocarditis

Current Opinion in Cardiology, 2019
The purpose of this study is to summarize and highlight the recent literature regarding immune checkpoint inhibitor myocarditis.The use of immune checkpoint inhibitors, a promising form of immunotherapy, is rapidly increasing in oncology. These drugs have been recently found to cause a fulminant myocarditis associated with a high-case fatality rate ...
Jayant, Raikhelkar, Nir, Uriel
openaire   +2 more sources

Immune Checkpoint Therapy in Melanoma

The Cancer Journal, 2016
Checkpoint-blocking antibodies have transformed cancer therapy, and the treatment of patients with metastatic melanoma has led the revolution. Herein, we review the current clinical data supporting the use of checkpoint-blocking antibodies in the treatment of melanoma and highlight outstanding clinical questions and unmet clinical needs.
openaire   +2 more sources

Combined Immune Checkpoint Blockade

Seminars in Oncology, 2015
There are very few tumor types for which chemotherapy regimens are regularly curative; notable exceptions include testicular cancer and Hodgkin's lymphoma. In both cases combination chemotherapy approaches are required. Thus, it would seem only logical that combination immunotherapy approaches will be required to induce long-term remissions in the ...
openaire   +2 more sources

Immune Checkpoint Inhibitors in Gliomas

Current Oncology Reports, 2017
Malignant gliomas result in disproportionately high morbidity and mortality compared with other primary tumors, and progression of disease is inevitable. Novel therapies to improve outcomes are needed and immune checkpoint inhibitors hold significant promise.A limited body of preclinical evidence suggests that checkpoint inhibitors may be effective ...
Aaron C, Tan   +2 more
openaire   +2 more sources

Checkpoints in antibacterial immunity

Research in Immunology, 1998
Flesch, I.   +3 more
openaire   +3 more sources

Targeting immune checkpoints in lymphoma

Current Opinion in Hematology, 2015
The purpose of this article is to discuss the tumor microenvironment in lymphoma, and to review potential immune targets that are now becoming relevant because of clinical responses seen with the use of immune checkpoint inhibitors.Recent data have shown that cells within the immune microenvironment in lymphoma express programmed death ligand-1 (PD-L1)
openaire   +2 more sources

The Broadening Scope of Oral Mucositis and Oral Ulcerative Mucosal Toxicities of Anticancer Therapies

Ca-A Cancer Journal for Clinicians, 2022
Stephen Sonis   +2 more
exaly  

Home - About - Disclaimer - Privacy